| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/15/2004 | CA2489590A1 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 07/14/2004 | EP1437592A1 Novel screening method using prokineticin receptor |
| 07/14/2004 | EP1437358A1 Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient |
| 07/14/2004 | EP1437353A1 Alkyl ether derivatives or salts thereof |
| 07/14/2004 | EP1437352A1 Benzimidazole compound, process for producing the same, and use thereof |
| 07/14/2004 | EP1437351A1 Amine derivative |
| 07/14/2004 | EP1437339A1 Substituted benzoic acid derivatives exhibiting nf-kappa b inhibiting activity |
| 07/14/2004 | EP1437139A2 Method for protection against genotoxic mutagenesis |
| 07/14/2004 | EP1437138A1 Use of 7-oxo DHEA in the modulation of the metabolism of a dieting mammal |
| 07/14/2004 | EP1437134A1 Anti-influenza drugs |
| 07/14/2004 | EP1437133A1 Amines with antialcoholic agents |
| 07/14/2004 | EP1437131A1 Use of an ACE inhibitor for the prevention of diabetes in a patient with no preexisting congestive heart failure |
| 07/14/2004 | EP1436429A2 Targeted nucleic acid constructs and uses related thereto |
| 07/14/2004 | EP1436383A2 Secreted proteins |
| 07/14/2004 | EP1436382A2 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 07/14/2004 | EP1436334A1 Polymers with structure-defined functions |
| 07/14/2004 | EP1436330A2 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 07/14/2004 | EP1436329A1 Anti-pdgf antibodies and methods for producing engineered antibodies |
| 07/14/2004 | EP1436318A2 Ncam binding compounds |
| 07/14/2004 | EP1436313A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 07/14/2004 | EP1436298A1 Himbacine analogues as thrombin receptor antagonists |
| 07/14/2004 | EP1436295A2 Crystalline forms of valacyclovir hydrochloride |
| 07/14/2004 | EP1436293A1 Polycyclic compounds having anti-tumor activity |
| 07/14/2004 | EP1436292A1 5-methoxy-8-aryl-[1,2,4]triazolo[1,5-a]pyridine derivatives as adenosine receptor antagonists |
| 07/14/2004 | EP1436291A2 Indolizines as kinase protein inhibitors |
| 07/14/2004 | EP1436290A1 Alkyne-aryl-naphthyridin-4(1h)-0ne derivatives as type iv phosphodiesterase inhibitor |
| 07/14/2004 | EP1436287A2 Small organic molecule regulators of cell proliferation |
| 07/14/2004 | EP1436285A2 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles |
| 07/14/2004 | EP1436283A1 Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof |
| 07/14/2004 | EP1436281A1 Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 07/14/2004 | EP1436279A1 Chemical compounds |
| 07/14/2004 | EP1436273A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof |
| 07/14/2004 | EP1436271A1 Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 07/14/2004 | EP1436269A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1436268A1 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them |
| 07/14/2004 | EP1436267A1 Lactam derivatives as antagonists for human 11cby receptors |
| 07/14/2004 | EP1436266A2 Methods and compositions of novel triazine compounds |
| 07/14/2004 | EP1436264A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 07/14/2004 | EP1436259A1 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors |
| 07/14/2004 | EP1436258A2 Ph-dependent nmda receptor antagonists |
| 07/14/2004 | EP1436257A1 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3 |
| 07/14/2004 | EP1436253A1 Acylsulfonamides as inhibitors of steroid sulfatase |
| 07/14/2004 | EP1436252A1 Hydroxyfattysulfonic acid analogs |
| 07/14/2004 | EP1436249A2 Muscarinic agonists |
| 07/14/2004 | EP1436247A1 Novel-beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 07/14/2004 | EP1436008A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 07/14/2004 | EP1436000A2 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 07/14/2004 | EP1435999A1 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone |
| 07/14/2004 | EP1435997A1 Method for treating hepatitis c virus infection in treatment failure patients |
| 07/14/2004 | EP1435992A2 Chemokines as adjuvants of immune response |
| 07/14/2004 | EP1435989A1 Ptp1b inhibitors and ligands |
| 07/14/2004 | EP1435988A1 Improved use of antitumoral compound in cancer therapy |
| 07/14/2004 | EP1435986A2 Igf-binding protein-derived peptide or small molecule |
| 07/14/2004 | EP1435971A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |
| 07/14/2004 | EP1435968A1 Combinations comprising cox-2 inhibitors and aspirin |
| 07/14/2004 | EP1435965A2 Pharmaceutical compositions and methods for treating cancer |
| 07/14/2004 | EP1435963A2 Reduced toxicity cisplatin formulations and methods for using the same |
| 07/14/2004 | EP1435960A1 Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists |
| 07/14/2004 | EP1435958A1 Use of phosphorodiesterase iv inhibitors |
| 07/14/2004 | EP1435957A2 Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes |
| 07/14/2004 | EP1435955A2 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 07/14/2004 | EP1435952A1 8-amino- 1,2,4]triazolo 1,5-a]pyridine-6-carboxylic acid amide |
| 07/14/2004 | EP1435950A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435949A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435948A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 07/14/2004 | EP1435947A1 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer |
| 07/14/2004 | EP1435944A1 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 07/14/2004 | EP1435943A2 Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug for treating dyskinesia |
| 07/14/2004 | EP1435942A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435941A2 Wortmannin analogs and methods of using same |
| 07/14/2004 | EP1435936A1 5'-carbamoyl-1,1-biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435934A1 5'-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435933A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435927A2 Method for treating skin disorders |
| 07/14/2004 | EP1435925A2 Gap junctions and edhf |
| 07/14/2004 | EP1435921A1 Use of a multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia |
| 07/14/2004 | EP1435914A1 Stable galenic freeze-dried pharmaceutical preparation of recombined carbohydrate-binding polypeptides |
| 07/14/2004 | EP1435899A1 A composition for promoting hair growth |
| 07/14/2004 | EP1435894A2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 07/14/2004 | EP1435786A1 Pesticidal formulations |
| 07/14/2004 | EP1372689B1 Use of ikk-beta inhibitors and method for discovery of said inhibitors |
| 07/14/2004 | EP1365760A4 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 07/14/2004 | EP1345979B1 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters |
| 07/14/2004 | EP1315793A4 Methods for culturing human lung mast cells and uses thereof |
| 07/14/2004 | EP1254120B1 Use of pyrimidine endothelin antagonists in companion animals |
| 07/14/2004 | EP1235803B1 Urea compounds having muscarinic receptor antagonist activity |
| 07/14/2004 | EP1228067B1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 07/14/2004 | EP1224179B1 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/14/2004 | EP1150667B1 Cyclohexenone long-chain alcohol for treating amyotrophic lateral sclerosis |
| 07/14/2004 | EP1144368B1 Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| 07/14/2004 | EP1083924B1 Glucagon-like peptide-1 (glp-1) improves beta-cell response to glucose in subjects with impaired glucose tolerance |
| 07/14/2004 | EP1082133B1 Stable pharmaceutical formulations for igf/igfbp |
| 07/14/2004 | EP1037887B1 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
| 07/14/2004 | EP1017823B1 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 07/14/2004 | EP1014986B1 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST |
| 07/14/2004 | EP0983248B1 Analogs of duocarmycin and cc-1065 |
| 07/14/2004 | EP0961775B1 Purine l-nucleosides, analogs and uses thereof |
| 07/14/2004 | EP0948358B1 Stable liquid interferon formulations |
| 07/14/2004 | EP0934325B1 Mycophenolic bisphosphonate compounds |
| 07/14/2004 | EP0889907B1 MONOCLONAL ANTIBODIES BINDING HUMAN GROWTH HORMONE (hGH) |